In the WHO classification, CML and aCML belong to myeloproliferative neoplasms, the distinction is that CML is defined as BCR-ABL1 fusion-positive resulting from t (9, 22) (q34; q11), while aCML is rare and characterized molecularly with BCR-ABL1 fusion-negative, and it is emphasized that accurate histological diagnosis has been to be the key to predict the prognosis of the disease (1, 4). This evidence concerns the gene ABL1 and myeloproliferative disorder.